Susquehanna Reiterates a 'Positive' Rating on Ctrip.com (CTRP); Raises Price Target
CTRP Hot Sheet
Rating Summary:1 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Susquehanna reiterates a 'Positive' rating on Ctrip.com (Nasdaq: CTRP), raises price target to $50.
Susquehanna analyst says, "We believe Ctrip is experiencing faster growth from online bookings than from call centers. This trend should lead to long-term positives, including revenue growth opportunities from leisure travels and online ad, reduction in labor costs, but higher scalability, and a stickier customer base. Near term, better than expected booking volumes should result in upside to 2Q earnings (our 2Q revenue growth is upped to 20% Y/Y from 17% Y/Y). We reiterate our Positive rating on Ctrip shares, and increase our price target 22% to $50, based on our 2010 Non-GAAP earnings estimates."
To see more analyst ratings on CTRP Click Here.
Ctrip.com International, Ltd. (Ctrip) is a travel service provider for hotel accommodations, airline tickets and packaged tours in China.
Susquehanna analyst says, "We believe Ctrip is experiencing faster growth from online bookings than from call centers. This trend should lead to long-term positives, including revenue growth opportunities from leisure travels and online ad, reduction in labor costs, but higher scalability, and a stickier customer base. Near term, better than expected booking volumes should result in upside to 2Q earnings (our 2Q revenue growth is upped to 20% Y/Y from 17% Y/Y). We reiterate our Positive rating on Ctrip shares, and increase our price target 22% to $50, based on our 2010 Non-GAAP earnings estimates."
To see more analyst ratings on CTRP Click Here.
Ctrip.com International, Ltd. (Ctrip) is a travel service provider for hotel accommodations, airline tickets and packaged tours in China.
You May Also Be Interested In
- Conditions of Growth, Economic Analysis - Research Report on Vale (ADR) and Ctrip.com International, Ltd. (ADR)
- Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); Adjusting Estimates; Copaxone Still In Focus
- Barclays Reiterates an 'Equalweight' on Lexington Realty Trust (LXP); Growing Pipeline, But Waiting on Cash in 2013
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Susquehanna International Group of Companies, Life, Style and Real EstateSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
